🇨🇭·Jan 1, 1970Industry
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Publisher
N
Novartis News
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Novartis News
- Region
- Switzerland
- Scope
- Industry
- Published
- January 1, 1970
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on novartis.com
Leave the platform to read the original full article on the publisher site.
Source: Novartis News
Scope: Industry
Related coverage
More related coverage
Santen Pharmaceutical News/12h ago
当社名をかたるSNSなりすましアカウントに関する注意喚起
Santen Pharmaceutical News/12h ago
「健康経営優良法人2026（大規模法人部門）」に認定
Santen Pharmaceutical News/12h ago
S&P GlobalによるSustainability Yearbook Member 2026に選定
Santen Pharmaceutical News/12h ago